ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the gut microbiome, announced
today that Jeffrey Riley, President
& Chief Executive Officer, is scheduled to participate in an
analyst-led fireside chat with the Company's covering analyst,
Adnan Butt, at the 2016 RBC Capital
Markets Global Healthcare Conference on Tuesday, February 23, at 4:35 p.m. (ET) in the Holmes II room at the New
York Palace Hotel in New York.
A live webcast of Synthetic Biologics' fireside chat may be
accessed by logging onto the internet at
https://www.veracast.com/webcasts/rbc/healthcare2016/17116241334.cfm.
After the discussion, a replay will be archived and accessible for
90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development include: (1) SYN-004 which is designed to
protect the gut microbiome from the effects of certain commonly
used intravenous (IV) antibiotics for the prevention of C.
difficile infection and antibiotic-associated diarrhea (AAD),
and (2) SYN-010 which is intended to reduce the impact of methane
producing organisms in the gut microbiome to treat an underlying
cause of irritable bowel syndrome with constipation (IBS-C). In
collaboration with Intrexon Corporation (NYSE: XON), the Company is
developing a preclinical stage monoclonal antibody for the
prevention and treatment of Pertussis, and discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-participate-in-fireside-chat-at-rbc-capital-markets-global-healthcare-conference-300220874.html
SOURCE Synthetic Biologics, Inc.